Lonza to buy U.S. drug capsule maker Capsugel from KKR for $5.5 billion

Ridinger, CEO of Lonza, attends a news conference on the acquisition of Capsugel in BaselSwiss pharmaceutical supplier Lonza Group AG on Thursday announced a deal to buy Capsugel, a U.S. maker of capsules and other drug delivery systems, from KKR & Co LP for $5.5 billion in cash to broaden its product range. Shares of Lonza fell nearly 5 percent on concerns about the acquisition's cost, more than 60 percent of the company's market value, and a planned capital increase of up to 3.3 billion Swiss francs ($3.22 billion). The stock price had already fallen by 5.3 percent on Monday after Reuters reported Lonza was in advanced talks to purchase Capsugel from the private equity firm.

Source: Feed3

Leave a Reply

Your email address will not be published. Required fields are marked *